{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-25-000180","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.589077+00:00","generated_at":"2026-05-17T02:06:31.519299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M","bullets":["GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.","INGREZZA net sales $686.6M (+12% YoY) driven by record quarterly new and total prescriptions.","CRENESSITY launch generated $98.1M net sales with 540 new patient enrollment start forms.","FY2025 INGREZZA guidance reaffirmed at $2.50-2.55B; GAAP R&D $1.00-1.02B, SG&A $1.14-1.16B.","Initiated second Phase 3 trial for direclidine (schizophrenia); osavampator Phase 3 in MDD enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-25-000180","json":"https://secwatch.observer/filing/0000914475-25-000180.json","markdown":"https://secwatch.observer/filing/0000914475-25-000180.md","text":"https://secwatch.observer/filing/0000914475-25-000180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/0000914475-25-000180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/nbix-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:06:31.519299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}